Focused on data and drug development, SoftBank hunts new $1B biotech deals — report
SoftBank’s mammoth $1.1 billion investment in Vivek Ramaswamy’s Roivant Sciences won’t likely be its last in biotech.
Quoting sources familiar with the deal, Bloomberg is reporting that the Japanese group’s global $100 billion equity fund has begun a recruitment campaign for scientists with an eye to backing more companies that use new data technology to identify drugs with solid development potential.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.